JPRN-UMIN000023009已完成未知
Phase 2b study of combined immunotherapy with dinutuximab, interleukin-2, and G-CSF for high risk neuroblastoma - GD2-P2
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 31years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Synchronous or asynchronous (within 5 years) other cancer except carcinoma in situ or intramucosal carcinoma. 2. Active infection requires systemic therapy. 3. Epileptic seizures without control by anticonvulsants 4. Daily use of a steroid 5. Administration of immune globulin within 28 days 6. Abnormalities of ECG requires therapy. 7. Less than 30% of Fractional Shortening and less than 55% of Ejection Fraction in cardiac function within 28 days There is respiratory failure requiring 8. oxygen administration 9. Woman during pregnancy, or impossible to discontinue breast-feeding for 120 days after the final dose of study treatment. 10. Patient or the partner without intent to use birth control. 11. Inadequate physical condition judged by investigator. 12. Known investigational drugs allergy.
研究者
相似试验
招募中
1 期
IMMUWHYAdvanced stage intrahepatic biliary tract cancer (BTC)MedDRA version: 20.0Level: LLTClassification code: 10073077Term: Intrahepatic cholangiocarcinoma Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10008594Term: Cholangiocarcinoma non-resectable Class: 10029104CTIS2023-508314-42-00Institut fuer Klinische Krebsforschung IKF GmbH66
进行中（未招募）
不适用
Pilot phase II study of a combined immunotherapy protocol based on oral vaccination and direct intratumoral injection of Salmonella Typhi Ty21a Vivotif in metastatic cutaneous melanoma patients. - NDMetastatic stage III e IV M1a melanomaMedDRA version: 6.1Level: PTClassification code 10042551EUCTR2005-005775-15-ITISTITUTO EUROPEO DI ONCOLOGIA43
已完成
不适用
A Phase I Trial of Combined immunotherapy with nivolumab and interferon-beta in Patients with advanced melanoma.advanced melanomaJPRN-UMIN000020222Tohoku University Graduate School of Medicine9
已完成
1 期
A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancercolorectal cancerJPRN-UMIN000022082Yamaguchi University12
招募中
2 期
Phase II Study of Local Therapy Combined with Immune Checkpoint Inhibitor for Oligo-Progressive disease during First-line Immunotherapy in non-small cell lung canceron-small cell lung cancerOligo-Progressive diseaseJPRN-jRCTs031220630Takahashi Kazuhisa60